Gary Calandra

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

John F. DiPersio, Edward A. Stadtmauer, Auayporn Nademanee et al. · Blood · 2009 · 773 citations · Full text

Safety, Pharmacokinetics, and Antiviral Activity of AMD3100, a Selective CXCR4 Receptor Inhibitor, in HIV-1 Infection

Craig W. Hendrix, Ann C. Collier, Michael M. Lederman et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2004 · 362 citations

Cxcr4 Receptor Inhibitor, Medicine, Antiviral Activity +14

AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data

Gary Calandra, John M. McCarty, Joseph P. McGuirk et al. · Bone Marrow Transplantation · 2007 · 277 citations

Hematological Malignancy, Cell Therapy, Compassionate Use Data +9

Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization

Guido Tricot, Michele Cottler‐Fox, Gary Calandra · Bone Marrow Transplantation · 2009 · 88 citations

Hematological Malignancy, Oncology, Pathology +8

Pharmacokinetics and Pharmacodynamics of Plerixafor in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma

Douglas A. Stewart, Clayton A. Smith, Ron MacFarland et al. · Biology of Blood and Marrow Transplantation · 2009 · 88 citations · Full text